EU H2020 FET-OPEN PAN3DP CONSORTIUM PARTNER

POIETIS (POI)
www.poietis.com/en/

POIETIS is an innovative biotechnology company, whose mission is to design, develop and market innovative solutions based on Laser-Assisted 3D Bioprinting to support Researchers and Physicians in the emergence of personalized medicine.

Winner of the 2014 ILab Contest (French National Competition for Innovative start-up Creation of the Ministry of Research, Creation-Development category) and the 2016 Worldwide Innovation Contest, Poietis is the only company to use the Laser-Assisted 3D Bioprinting technology, initially developed at the INSERM and Bordeaux University. POIETIS’ areas of expertise are 3D Bioprinting, Personalized therapies, Physiological tissue models, Regenerative Medicine, Tissue Engineering.

The laser-assisted bioprinting technology developed by POIETIS to produce biological tissue can position cells in 3D with extremely high cellular resolution (on the order of ten microns) and cellular viability (over 95%). Poietis will contribute to the consortium by bringing in this unique bioprinting technology and will participate together with all partners to the design and development of physiological 3D pancreatic-tissue models.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PAN3DP CONSORTIUM PARTNERS:

de Duve Institute-UCL (DDI)
ETH Zürich
King’s College London (KCL)
Poietis (POI)
Technion Israel Institute of Technology (TEC)
Tel Aviv University (TAU)